Where Will Reddit Stock Be In 5 Years?
On a wet March morning last year, the famously orange…
Sell
30
MIRA Quote, Financials, Valuation and Earnings
Last price:
$1.25
Seasonality move
:
138.42%
Day range:
$1.21 - $1.28
52-week range:
$0.51 - $5.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
16.73x
Volume:
501.8K
Avg. volume:
512.5K
1-year change:
77.78%
Market cap:
$21.7M
Revenue:
--
EPS (TTM):
-$0.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIRA
Mira Pharmaceuticals
|
-- | -$0.15 | -- | -18.18% | $17.75 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 6.13% | 68.77% | $140.89 |
|
ICAD
icad
|
$4.5M | -$0.06 | -4.33% | -21.43% | $3.75 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIRA
Mira Pharmaceuticals
|
$1.28 | $17.75 | $21.7M | -- | $0.00 | 0% | -- |
|
ABT
Abbott Laboratories
|
$132.28 | $140.89 | $230.1B | 17.16x | $0.59 | 1.72% | 5.46x |
|
ICAD
icad
|
$3.77 | $3.75 | $102.8M | -- | $0.00 | 0% | 5.11x |
|
NBY
NovaBay Pharmaceuticals
|
$0.62 | $0.85 | $3.6M | -- | $0.00 | 0% | 0.16x |
|
OGEN
Oragenics
|
$4.37 | $1.00 | $3.1M | -- | $0.00 | 0% | 1.40x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIRA
Mira Pharmaceuticals
|
-- | -1.926 | -- | -- |
|
ABT
Abbott Laboratories
|
21.34% | 0.731 | 6.18% | 1.27x |
|
ICAD
icad
|
-- | 1.034 | -- | 3.47x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIRA
Mira Pharmaceuticals
|
-- | -$1.8M | -- | -- | -- | -$1.6M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.7B | 23.5% | 31.31% | 18.43% | $933M |
|
ICAD
icad
|
$4.2M | -$1.1M | -17.16% | -17.16% | -23.16% | -$197K |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Mira Pharmaceuticals vs. Competitors
-
Which has Higher Returns MIRA or ABT?
Abbott Laboratories has a net margin of -- compared to Mira Pharmaceuticals's net margin of 12.79%. Mira Pharmaceuticals's return on equity of -- beat Abbott Laboratories's return on equity of 31.31%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMira Pharmaceuticals-- -$0.11 -- ABTAbbott Laboratories56.86% $0.76 $62.3B -
What do Analysts Say About MIRA or ABT?
Mira Pharmaceuticals has a consensus price target of $17.75, signalling upside risk potential of 1286.72%. On the other hand Abbott Laboratories has an analysts' consensus of $140.89 which suggests that it could grow by 6.51%. Given that Mira Pharmaceuticals has higher upside potential than Abbott Laboratories, analysts believe Mira Pharmaceuticals is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings MIRAMira Pharmaceuticals0 1 0 ABTAbbott Laboratories12 10 0 -
Is MIRA or ABT More Risky?
Mira Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.647%.
-
Which is a Better Dividend Stock MIRA or ABT?
Mira Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.72% to investors and pays a quarterly dividend of $0.59 per share. Mira Pharmaceuticals pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MIRA or ABT?
Mira Pharmaceuticals quarterly revenues are --, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Mira Pharmaceuticals's net income of -$1.8M is lower than Abbott Laboratories's net income of $1.3B. Notably, Mira Pharmaceuticals's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 17.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mira Pharmaceuticals is -- versus 5.46x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMira Pharmaceuticals-- -- -- -$1.8M ABTAbbott Laboratories5.46x 17.16x $10.4B $1.3B
-
Which has Higher Returns MIRA or ICAD?
icad has a net margin of -- compared to Mira Pharmaceuticals's net margin of -17.09%. Mira Pharmaceuticals's return on equity of -- beat icad's return on equity of -17.16%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMira Pharmaceuticals-- -$0.11 -- ICADicad85.95% -$0.03 $30.8M -
What do Analysts Say About MIRA or ICAD?
Mira Pharmaceuticals has a consensus price target of $17.75, signalling upside risk potential of 1286.72%. On the other hand icad has an analysts' consensus of $3.75 which suggests that it could fall by -0.53%. Given that Mira Pharmaceuticals has higher upside potential than icad, analysts believe Mira Pharmaceuticals is more attractive than icad.
Company Buy Ratings Hold Ratings Sell Ratings MIRAMira Pharmaceuticals0 1 0 ICADicad0 4 0 -
Is MIRA or ICAD More Risky?
Mira Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison icad has a beta of 1.379, suggesting its more volatile than the S&P 500 by 37.881%.
-
Which is a Better Dividend Stock MIRA or ICAD?
Mira Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. icad offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mira Pharmaceuticals pays -- of its earnings as a dividend. icad pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or ICAD?
Mira Pharmaceuticals quarterly revenues are --, which are smaller than icad quarterly revenues of $4.9M. Mira Pharmaceuticals's net income of -$1.8M is lower than icad's net income of -$833K. Notably, Mira Pharmaceuticals's price-to-earnings ratio is -- while icad's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mira Pharmaceuticals is -- versus 5.11x for icad. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMira Pharmaceuticals-- -- -- -$1.8M ICADicad5.11x -- $4.9M -$833K
-
Which has Higher Returns MIRA or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Mira Pharmaceuticals's net margin of -49.65%. Mira Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMira Pharmaceuticals-- -$0.11 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About MIRA or NBY?
Mira Pharmaceuticals has a consensus price target of $17.75, signalling upside risk potential of 1286.72%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.5%. Given that Mira Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Mira Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MIRAMira Pharmaceuticals0 1 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is MIRA or NBY More Risky?
Mira Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock MIRA or NBY?
Mira Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mira Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or NBY?
Mira Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Mira Pharmaceuticals's net income of -$1.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Mira Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mira Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMira Pharmaceuticals-- -- -- -$1.8M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns MIRA or OGEN?
Oragenics has a net margin of -- compared to Mira Pharmaceuticals's net margin of --. Mira Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MIRAMira Pharmaceuticals-- -$0.11 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About MIRA or OGEN?
Mira Pharmaceuticals has a consensus price target of $17.75, signalling upside risk potential of 1286.72%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 586.57%. Given that Mira Pharmaceuticals has higher upside potential than Oragenics, analysts believe Mira Pharmaceuticals is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings MIRAMira Pharmaceuticals0 1 0 OGENOragenics0 1 0 -
Is MIRA or OGEN More Risky?
Mira Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock MIRA or OGEN?
Mira Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mira Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or OGEN?
Mira Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Mira Pharmaceuticals's net income of -$1.8M is higher than Oragenics's net income of -$2.2M. Notably, Mira Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mira Pharmaceuticals is -- versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMira Pharmaceuticals-- -- -- -$1.8M OGENOragenics1.40x -- -- -$2.2M
-
Which has Higher Returns MIRA or TOVX?
Theriva Biologics has a net margin of -- compared to Mira Pharmaceuticals's net margin of --. Mira Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MIRAMira Pharmaceuticals-- -$0.11 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About MIRA or TOVX?
Mira Pharmaceuticals has a consensus price target of $17.75, signalling upside risk potential of 1286.72%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Mira Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Mira Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MIRAMira Pharmaceuticals0 1 0 TOVXTheriva Biologics1 1 0 -
Is MIRA or TOVX More Risky?
Mira Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock MIRA or TOVX?
Mira Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mira Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or TOVX?
Mira Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Mira Pharmaceuticals's net income of -$1.8M is higher than Theriva Biologics's net income of -$4.3M. Notably, Mira Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mira Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMira Pharmaceuticals-- -- -- -$1.8M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
47
RGC alert for Jun 18
Regencell Bioscience Holdings [RGC] is down 26.1% over the past day.
Sell
20
ENPH alert for Jun 18
Enphase Energy [ENPH] is up 2.66% over the past day.
Sell
26
FSLR alert for Jun 18
First Solar [FSLR] is down 0.67% over the past day.
